{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Dallas&page=44&state=Texas", "query": { "state": "Texas", "city": "Dallas", "page": 44 }, "page_size": 10 }, "pagination": { "page": 44, "page_size": 10, "total_count": 13791, "total_pages": 1380, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Dallas&page=45&state=Texas&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Dallas&page=43&state=Texas&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T14:22:54.999Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00163657", "title": "Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "End Stage Liver Disease", "Hepatitis C" ], "interventions": [ { "name": "Daclizumub", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "MMF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 312, "start_date": "2002-07", "completion_date": "2007-01", "has_results": true, "last_update_posted_date": "2017-01-12", "last_synced_at": "2026-11-15T14:22:54.999Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00163657" }, { "nct_id": "NCT05936619", "title": "MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Paralysis; Quadriplegic", "Quadraplegia", "Tetraplegia", "Tetraplegic Motor Dysfunction Following Brainstem or Spinal Cord Injury", "Cervical Spinal Cord Injury", "Amyotrophic Lateral Sclerosis (ALS)", "Brainstem Stroke", "Paralysis", "Brain-computer Interface", "BCI" ], "interventions": [ { "name": "Mind Extender (MindEx)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Nader Pouratian", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 2, "start_date": "2026-02-20", "completion_date": "2031-09-01", "has_results": false, "last_update_posted_date": "2026-10-30", "last_synced_at": "2026-11-15T14:22:54.999Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05936619" }, { "nct_id": "NCT02311777", "title": "Pre-operative Pregabalin and Ketamine to Prevent Phantom Pain", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Phantom Pain" ], "interventions": [ { "name": "Pregabalin", "type": "DRUG" }, { "name": "Ketamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2015-05-15", "completion_date": "2017-09-20", "has_results": false, "last_update_posted_date": "2018-12-19", "last_synced_at": "2026-11-15T14:22:54.999Z", "location_count": 2, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02311777" }, { "nct_id": "NCT05605093", "title": "Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Shionogi Protease Inhibitor (S-217622)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 602, "start_date": "2022-12-23", "completion_date": "2025-10-28", "has_results": true, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-11-15T14:22:54.999Z", "location_count": 103, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Fresno, California + 75 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05605093" }, { "nct_id": "NCT05949593", "title": "Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Geographic Atrophy" ], "interventions": [ { "name": "Tinlarebant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Belite Bio, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "60 Years to 85 Years" }, "enrollment_count": 429, "start_date": "2023-07-27", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-11-15T14:22:54.999Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05949593" }, { "nct_id": "NCT07144280", "title": "A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Carcinoma", "Non-Small Cell Lung Cancer Metastatic", "Non-Small Cell Lung Carcinoma" ], "interventions": [ { "name": "PF-08046054", "type": "DRUG" }, { "name": "Docetaxel monotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 680, "start_date": "2025-09-29", "completion_date": "2032-03-10", "has_results": false, "last_update_posted_date": "2026-11-05", "last_synced_at": "2026-11-15T14:22:54.999Z", "location_count": 262, "location_summary": "Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 177 more", "locations": [ { "city": "Alabaster", "state": "Alabama" }, { "city": "Bessemer", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT07144280" }, { "nct_id": "NCT01404832", "title": "The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Gastroesophageal Reflux Disease", "Eosinophilic Esophagitis" ], "interventions": [ { "name": "Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dallas VA Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2007-10", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2013-02-27", "last_synced_at": "2026-11-15T14:22:54.999Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01404832" }, { "nct_id": "NCT02511132", "title": "A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ewing's Sarcoma" ], "interventions": [ { "name": "Vigil", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Gradalis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 22, "start_date": "2016-02-10", "completion_date": "2020-12-23", "has_results": true, "last_update_posted_date": "2022-12-22", "last_synced_at": "2026-11-15T14:22:54.999Z", "location_count": 6, "location_summary": "Little Rock, Arkansas • Miami, Florida • New York, New York + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02511132" }, { "nct_id": "NCT06026332", "title": "ADSTILADRIN Early Utilization and Outcomes in the Real World Setting", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "ADSTILADRIN", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ferring Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2023-09-15", "completion_date": "2026-01-15", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-11-15T14:22:54.999Z", "location_count": 31, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 25 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06026332" }, { "nct_id": "NCT00658632", "title": "Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastroesophageal Reflux Disease (GERD)" ], "interventions": [ { "name": "Rabeprazole sodium", "type": "DRUG" }, { "name": "Esomeprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1397, "start_date": "2008-02", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2016-05-04", "last_synced_at": "2026-11-15T14:22:54.999Z", "location_count": 85, "location_summary": "Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 73 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Sherwood", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00658632" } ] }